Drug:
Reaction: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION
20260101 - 20261231
No. 101 - 200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 101 | 26939432 |
JP |
9 | 1 |
Duodenal ulcer, Oropharyngeal pain, Cough, Malignant neoplasm progression, Inappropriate schedule of product administration, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 102 | 26939551 |
US |
2 | |
Gastrointestinal disorder, Fear of injection, Constipation, Inappropriate schedule of product administration, |
||||
TIRZEPATIDE, TIRZEPATIDE, |
||||
| 103 | 26939616 |
US |
74 | 2 |
Visual impairment, Drug dose omission by device, Device difficult to use, Inappropriate schedule of product administration, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 104 | 26939934 |
US |
1 | |
Inappropriate schedule of product administration, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, FLUOXETINE HYDROCHLORIDE, EZETIMIBE, LORAZEPAM, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, MIRTAZAPINE, SOTATERCEPT-CSRK, PRAMIPEXOLE DIHYDROCHLORIDE, TORSEMIDE, TADALAFIL, |
||||
| 105 | 26940051 |
CA |
30 | |
Haematochezia, Papule, Pruritus, Dry skin, Inappropriate schedule of product administration, |
||||
INFLIXIMAB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, MESALAMINE, PREDNISONE, |
||||
| 106 | 26931182 |
US |
2 | |
Inappropriate schedule of product administration, Rash, |
||||
DUPILUMAB, DUPILUMAB, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, ESCITALOPRAM OXALATE, ESCITALOPRAM, TIRZEPATIDE, |
||||
| 107 | 26931210 |
US |
23 | 2 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 108 | 26931485 |
US |
||
Loss of therapeutic response, Inappropriate schedule of product administration, |
||||
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, |
||||
| 109 | 26931587 |
CA |
65 | 2 |
Psoriatic arthropathy, Surgery, Inappropriate schedule of product administration, |
||||
USTEKINUMAB-AUUB, |
||||
| 110 | 26931691 |
CA |
76 | 2 |
Myasthenia gravis, Drug ineffective, Injection site bruising, Inappropriate schedule of product administration, |
||||
ROZANOLIXIZUMAB, |
||||
| 111 | 26931764 |
EU |
69 | 2 |
Diarrhoea, Abdominal pain, Mucosal inflammation, Nausea, Product administration issue, Inappropriate schedule of product administration, |
||||
METHOTREXATE SODIUM, |
||||
| 112 | 26931771 |
US |
2 | |
Dermatitis atopic, Rash, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 113 | 26931772 |
US |
1 | |
Dermatitis atopic, Inappropriate schedule of product administration, Paraesthesia, Peripheral swelling, |
||||
DUPILUMAB, |
||||
| 114 | 26932029 |
US |
54 | |
Liver disorder, Inappropriate schedule of product administration, |
||||
PALTUSOTINE, PALTUSOTINE, |
||||
| 115 | 26932057 |
60 | ||
Abdominal pain, Inappropriate schedule of product administration, |
||||
PALTUSOTINE, |
||||
| 116 | 26932085 |
CA |
50 | |
Thunderclap headache, Harvey-Bradshaw index increased, Mouth ulceration, Conjunctival haemorrhage, Weight decreased, Condition aggravated, Urinary tract infection, Tooth infection, Arthralgia, Abdominal pain, Off label use, Intentional dose omission, Inappropriate schedule of product administration, Incorrect dose administered, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, VORTIOXETINE, LISDEXAMFETAMINE DIMESYLATE, METHYLPHENIDATE HYDROCHLORIDE, ESTRADIOL, PROGESTERONE, |
||||
| 117 | 26932115 |
CA |
29 | |
Colitis ulcerative, Migraine, Off label use, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, ALBUTEROL SULFATE, OLANZAPINE, SERTRALINE, DROSPIRENONE AND ETHINYL ESTRADIOL, FLUTICASONE FUROATE, CICLESONIDE, METHYLPHENIDATE HYDROCHLORIDE, |
||||
| 118 | 26932183 |
CA |
47 | |
Blood pressure increased, Colitis ulcerative, Inappropriate schedule of product administration, Suspected off label use, Product dose omission issue, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 119 | 26932188 |
CA |
76 | |
Macular degeneration, Cough, Dyspnoea, Nasopharyngitis, Underdose, Inappropriate schedule of product administration, Off label use, Product dose omission issue, Intentional dose omission, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 120 | 26932191 |
CA |
76 | |
Hip fracture, Diarrhoea, Off label use, Inappropriate schedule of product administration, Intentional dose omission, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 121 | 26932238 |
CA |
31 | |
Blood potassium decreased, Paranasal sinus discomfort, Sinus headache, Inappropriate schedule of product administration, Intentional product use issue, Overdose, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 122 | 26932331 |
US |
2 | |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 123 | 26932343 |
IL |
2 | |
Haematemesis, Inappropriate schedule of product administration, |
||||
| 124 | 26932409 |
US |
2 | |
Dermatitis atopic, Rash macular, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 125 | 26932416 |
US |
20 | 1 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 126 | 26932468 |
US |
77 | 1 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 127 | 26932487 |
US |
7 | 1 |
Hiatus hernia, Vomiting, Throat irritation, Gastrooesophageal reflux disease, Condition aggravated, Gastroenteritis, Diarrhoea, Decreased appetite, Injection site pain, Injection site mass, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 128 | 26932517 |
US |
55 | 2 |
Asthma, Inappropriate schedule of product administration, Product storage error, |
||||
DUPILUMAB, |
||||
| 129 | 26932531 |
US |
2 | |
Adverse drug reaction, Inappropriate schedule of product administration, |
||||
DUPILUMAB, BUSPIRONE HYDROCHLORIDE, CELECOXIB, DULOXETINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE, METHOTREXATE, METHOTREXATE SODIUM, PANTOPRAZOLE, OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, PREDNISONE, PROPRANOLOL HYDROCHLORIDE, RANITIDINE, RIZATRIPTAN, TIZANIDINE, TOPIRAMATE, |
||||
| 130 | 26932540 |
US |
51 | 2 |
Inappropriate schedule of product administration, |
||||
BIMEKIZUMAB, |
||||
| 131 | 26932585 |
US |
1 | |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, CALCIUM, |
||||
| 132 | 26932654 |
US |
29 | 1 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 133 | 26932718 |
US |
46 | 1 |
Inappropriate schedule of product administration, Therapy interrupted, |
||||
BIMEKIZUMAB, |
||||
| 134 | 26932800 |
US |
69 | 1 |
Eczema, Therapeutic response shortened, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 135 | 26932846 |
US |
69 | 1 |
Sinusitis, Inappropriate schedule of product administration, |
||||
BIMEKIZUMAB, |
||||
| 136 | 26932853 |
CA |
24 | |
Breast mass, Malaise, Otorrhoea, Ear pain, Back pain, Nasopharyngitis, Pharyngitis streptococcal, Scarlet fever, Intentional dose omission, Inappropriate schedule of product administration, Overdose, Underdose, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 137 | 26933078 |
CA |
61 | |
Harvey-Bradshaw index increased, Weight decreased, Anal fissure, Inappropriate schedule of product administration, Drug level below therapeutic, Suspected off label use, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 138 | 26933208 |
CA |
25 | |
Haematochezia, Discomfort, Harvey-Bradshaw index increased, Anal fissure, Anal fistula, Cough, Muscle spasms, Nasopharyngitis, Urinary tract infection, Abdominal pain, Weight increased, Off label use, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 139 | 26933241 |
US |
88 | 2 |
Electrocardiogram QT prolonged, Ventricular tachycardia, Ventricular extrasystoles, Electrocardiogram T wave inversion, Inappropriate schedule of product administration, Drug interaction, |
||||
SOTALOL HYDROCHLORIDE, APIXABAN, LISINOPRIL, PIPERACILLIN SODIUM,TAZOBACTAM SODIUM, DOXYCYCLINE, DOXYCYCLINE HYCLATE, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE INJECTION, MAGNESIUM SULFATE, MAGNESIUM SULFATE HEPTAHYDRATE, MAGNESIUM SULFATE IN WATER FOR, |
||||
| 140 | 26933244 |
US |
1 | |
Eosinophilic oesophagitis, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 141 | 26933245 |
US |
57 | 1 |
Rash, Asthenia, Inappropriate schedule of product administration, |
||||
BELUMOSUDIL, |
||||
| 142 | 26933246 |
US |
1 | |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 143 | 26933252 |
US |
1 | |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 144 | 26933254 |
US |
34 | 2 |
Joint stiffness, Inappropriate schedule of product administration, Condition aggravated, |
||||
DUPILUMAB, AZELASTINE, BUPROPION, LORATADINE, LORATADINE TABLET, SECUKINUMAB, DICLOFENAC, DICLOFENAC SODIUM, VENLAFAXINE HYDROCHLORIDE, FAMOTIDINE, GABAPENTIN, HYDROXYCHLOROQUINE, |
||||
| 145 | 26933310 |
CA |
29 | |
Crohn^s disease, Influenza like illness, Myalgia, Inappropriate schedule of product administration, Suspected off label use, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 146 | 26933363 |
US |
67 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 147 | 26933369 |
US |
20 | 2 |
Pruritus, Injection site pain, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 148 | 26933399 |
US |
29 | 2 |
Fatigue, Inappropriate schedule of product administration, |
||||
BELUMOSUDIL, ACYCLOVIR, SULFAMETHOXAZOLE AND TRIMETHOPRIM, ISAVUCONAZONIUM SULFATE, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, MEDROXYPROGESTERONE ACETATE, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, PREDNISONE, CYCLOSPORINE, QUETIAPINE, |
||||
| 149 | 26933429 |
CA |
30 | |
Harvey-Bradshaw index increased, Malaise, Weight decreased, Off label use, Therapeutic response shortened, Product dose omission issue, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 150 | 26933435 |
CA |
47 | |
Haematochezia, Diarrhoea, Harvey-Bradshaw index increased, Arthralgia, Weight increased, Fatigue, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB, |
||||
| 151 | 26933454 |
US |
76 | 2 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 152 | 26933533 |
US |
82 | 1 |
Nasal polyps, Accidental exposure to product, Exposure via skin contact, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 153 | 26933534 |
US |
2 | |
Adverse event, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 154 | 26933568 |
US |
75 | 1 |
Accidental exposure to product, Exposure via skin contact, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 155 | 26933577 |
US |
22 | 2 |
Pruritus, Therapeutic response shortened, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 156 | 26933588 |
US |
60 | 1 |
Injection site pain, Dermatitis atopic, Inappropriate schedule of product administration, Product preparation issue, Pruritus, Dry skin, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 157 | 26933593 |
US |
60 | 2 |
Product dose omission issue, Inappropriate schedule of product administration, Injection site injury, Injection site haemorrhage, |
||||
TIRZEPATIDE, TIRZEPATIDE, |
||||
| 158 | 26933607 |
US |
2 | |
Illness, Eczema, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 159 | 26933696 |
US |
64 | 1 |
Dry skin, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 160 | 26933714 |
CA |
39 | |
Hospitalisation, Dependence, Mental disorder, Heart rate increased, Treatment noncompliance, Off label use, Product dose omission issue, Inappropriate schedule of product administration, Overdose, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 161 | 26933717 |
US |
11 | 1 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 162 | 26933783 |
US |
20 | 2 |
Photosensitivity reaction, Rash, Erythema, Fatigue, Pyrexia, Chills, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 163 | 26933823 |
US |
2 | |
Pruritus, Dermatitis atopic, Therapeutic response shortened, Inappropriate schedule of product administration, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 164 | 26933916 |
US |
2 | |
Glaucoma surgery, Product use complaint, Wrong technique in product usage process, Circumstance or information capable of leading to medication error, Inappropriate schedule of product administration, |
||||
PERFLUOROHEXYLOCTANE, PERFLUOROHEXYLOCTANE, |
||||
| 165 | 26933918 |
US |
42 | |
Inappropriate schedule of product administration, |
||||
MOGAMULIZUMAB-KPKC, |
||||
| 166 | 26933933 |
US |
76 | 1 |
Cataract operation, Inappropriate schedule of product administration, |
||||
PERFLUOROHEXYLOCTANE, CARVEDILOL, DOXYCYCLINE, DOXYCYCLINE HYCLATE, |
||||
| 167 | 26933958 |
CA |
37 | |
Concussion, COVID-19, Sinusitis, Intentional dose omission, Therapy interrupted, Intentional product use issue, Inappropriate schedule of product administration, Product distribution issue, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 168 | 26926655 |
US |
2 | |
Neuropathy peripheral, Musculoskeletal stiffness, Inappropriate schedule of product administration, |
||||
SARILUMAB, ROSUVASTATIN, VENLAFAXINE HYDROCHLORIDE, LOSARTAN POTASSIUM, LOSARTAN, MIRABEGRON, ESOMEPRAZOLE MAGNESIUM, AMLODIPINE BESYLATE, |
||||
| 169 | 26926668 |
CA |
2 | |
Hip surgery, Off label use, Inappropriate schedule of product administration, |
||||
IBRUTINIB, IBRUTINIB, IBRUTINIB, CISPLATIN, CYTARABINE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, RITUXIMAB, |
||||
| 170 | 26926952 |
US |
2 | |
Inappropriate schedule of product administration, Constipation, |
||||
TIRZEPATIDE, |
||||
| 171 | 26926988 |
US |
2 | |
Incorrect dose administered, Inappropriate schedule of product administration, |
||||
ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, |
||||
| 172 | 26927026 |
CA |
64 | |
Crohn^s disease, Diarrhoea, Fatigue, Arthralgia, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, SITAGLIPTIN, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, MELOXICAM, CANDESARTAN, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, HYDROCHLOROTHIAZIDE, NIFEDIPINE, BISOPROLOL FUMARATE, CLOPIDOGREL, INSULIN LISPRO, INSULIN DEGLUDEC, ERGOCALCIFEROL, COLCHICINE, PREDNISONE, |
||||
| 173 | 26927069 |
US |
1 | |
Inappropriate schedule of product administration, |
||||
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE ORAL, |
||||
| 174 | 26927115 |
US |
78 | 1 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 175 | 26927132 |
US |
2 | |
Inappropriate schedule of product administration, |
||||
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE ORAL, DUPILUMAB, |
||||
| 176 | 26927291 |
US |
1 | |
Iritis, Inappropriate schedule of product administration, Off label use, |
||||
AVACINCAPTAD PEGOL, AVACINCAPTAD PEGOL, AVACINCAPTAD PEGOL, AVACINCAPTAD PEGOL, AVACINCAPTAD PEGOL, AVACINCAPTAD PEGOL, |
||||
| 177 | 26927322 |
US |
1 | |
Inappropriate schedule of product administration, |
||||
ESKETAMINE HYDROCHLORIDE, ESKETAMINE HYDROCHLORIDE, ESKETAMINE HYDROCHLORIDE, |
||||
| 178 | 26927484 |
US |
81 | 2 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, CALCIUM, PAROXETINE, PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE HEMIHYDRATE, |
||||
| 179 | 26927589 |
US |
2 | |
Pneumonia, Systemic lupus erythematosus, Stress, Insomnia, Inappropriate schedule of product administration, |
||||
| 180 | 26927598 |
CA |
78 | |
Frequent bowel movements, Harvey-Bradshaw index increased, Abdominal pain, Arthralgia, Overdose, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, DABIGATRAN ETEXILATE, PANTOPRAZOLE, COLESEVELAM, |
||||
| 181 | 26927831 |
CA |
49 | |
Weight decreased, Dyslipidaemia, Blood pressure increased, Off label use, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, METHOTREXATE, METHOTREXATE SODIUM, FOLIC ACID, ROSUVASTATIN, |
||||
| 182 | 26927856 |
US |
2 | |
Fatigue, Injection site reaction, Inappropriate schedule of product administration, |
||||
MEPOLIZUMAB, |
||||
| 183 | 26927922 |
US |
1 | |
Renal impairment, Cystitis, Inappropriate schedule of product administration, Pain, |
||||
SODIUM ZIRCONIUM CYCLOSILICATE, |
||||
| 184 | 26927979 |
US |
43 | 2 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 185 | 26928049 |
CA |
71 | |
Surgery, Hospitalisation, Femur fracture, Fall, Upper limb fracture, Weight decreased, Intentional dose omission, Product dose omission issue, Underdose, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 186 | 26928081 |
78 | ||
Blood pressure decreased, Inappropriate schedule of product administration, Drug ineffective, |
||||
METOPROLOL TARTRATE, ERGOCALCIFEROL, ALLOPURINOL, CALCIUM, FOLIC ACID, FUROSEMIDE, PREDNISONE, SIMVASTATIN, WARFARIN, |
||||
| 187 | 26928238 |
US |
87 | 2 |
Diverticulum intestinal, Swelling, Back pain, Inappropriate schedule of product administration, |
||||
BIMEKIZUMAB, |
||||
| 188 | 26928444 |
US |
71 | 2 |
Fatigue, Inappropriate schedule of product administration, Condition aggravated, Product use in unapproved indication, |
||||
DUPILUMAB, TIRZEPATIDE, OMEPRAZOLE MAGNESIUM, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, ERGOCALCIFEROL, |
||||
| 189 | 26928799 |
US |
20 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 190 | 26928992 |
US |
86 | 2 |
Choking, Haemorrhage, Wrong technique in product usage process, Incorrect dose administered, Inappropriate schedule of product administration, Product size issue, |
||||
ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, |
||||
| 191 | 26929020 |
US |
54 | |
Inappropriate schedule of product administration, Malaise, |
||||
EVOLOCUMAB, |
||||
| 192 | 26929539 |
US |
2 | |
Nausea, Inappropriate schedule of product administration, |
||||
| 193 | 26929554 |
KR |
2 | |
Red blood cell transfusion, Inappropriate schedule of product administration, Hospitalisation, Inappropriate schedule of product administration, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, |
||||
| 194 | 26929624 |
US |
69 | 1 |
Infection, Product distribution issue, Inappropriate schedule of product administration, |
||||
LENALIDOMIDE, |
||||
| 195 | 26929915 |
US |
10 | 2 |
Eczema, Dry skin, Scab, Pruritus, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 196 | 26929921 |
US |
5 | 1 |
Eye irritation, Pruritus, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 197 | 26929989 |
US |
90 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 198 | 26930270 |
US |
2 | |
Condition aggravated, Inappropriate schedule of product administration, |
||||
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE, |
||||
| 199 | 26930699 |
PH |
||
Death, Inappropriate schedule of product administration, Wrong technique in product usage process, Prescribed underdose, Product prescribing issue, |
||||
TOLVAPTAN, TOLVAPTAN, |
||||
| 200 | 26930748 |
US |
19 | 2 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30